$LPCN News

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

Lipocine Q2 EPS $(0.32) Beats $(0.43) Estimate, Sales $190.099K Beat $156.500K Estimate

Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

Lipocine To Announce Phase 3 Data For LPCN 1154 Treatment For Postpartum Depression On May 26

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

CORRECTION: Lipocine Q1 EPS $(0.54) Misses $(0.48) Estimate, Sales $119.397K Miss $162.500K Estimate

Lipocine Q1 EPS $(0.54) Misses $(0.48) Estimate, Sales $119.397M Beat $162.500K Estimate

Lipocine Appoints R. Dana Ono As Chairman Of The Board On April 20, 2026

What's Going On With Lipocine Stock On Monday?

HC Wainwright & Co. Downgrades Lipocine to Neutral

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Lipocine shares are trading lower after the company's LPCN 1154 missed its Phase 3 primary endpoint in postpartum depression.

Lipocine shares are trading lower after the company's LPCN 1154 missed its Phase 3 primary endpoint in postpartum depression.

Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Lipocine's LPCN 1154 Misses Phase 3 Primary Endpoint in Postpartum Depression; Shows Early Efficacy Signals In Patients With Prior Psychiatric History And Maintains Favorable Safety Profile

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025